Shares of TG Therapeutics (NASDAQ: TGTX) were up by 18% as of mid-afternoon Tuesday after reports that the biotech's multiple sclerosis therapy Briumvi would have better-than-expected sales in its first quarter. The stock set a 52-week high of $22.91 earlier in the afternoon.

On Dec. 28, the Food and Drug Administration (FDA) approved Briumvi as a treatment for adults with relapsing multiple sclerosis. The company launched the anti-CD20 monoclonal antibody on the market on Jan. 26. CD20 is a protein found in white blood cells. According to industry news site BioPharmaCatalyst, Cantor analyst Prakhar Agrawal said that Briumvi did $3.3 million in March sales after doing $500,000 in revenue in February. 

This is a huge deal for TG Therapeutics: Briumvi is its second marketed product, and it's off to a great start. The company's pipeline includes four other programs, all to treat B cell malignancies. Briumvi will likely be approved in Europe soon as well. On March 31, the European Medicines Agency's Committee for Medicinal Products for Human Use gave the injectable therapy a positive opinion.

Continue reading

Source Fool.com